West Pharmaceutical Services, Inc.· WST
🇺🇸 US · LargeSP500NYSE
- Price
- $348.76
- Day
- +0.24%
- Mkt Cap
- $24.54B
- 52W Range
- $223.83 – $386.00
- Volume
- 347.9K
- Beta
- 1.16
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
West Pharmaceuticals stock moved higher following another quarter of broad-based growth, driven by continued demand for high-value biologics packaging and proprietary delivery components. Tyler Technologies underperformed during the quarter despite delivering solid financial results that met management's guidance. We were attracted to Knowles' accelerating organic growth, expanding margins, and exposure to several attractive long-term secular trends.
Read full article
Dimensional Fund Advisors LP lifted its stake in shares of West Pharmaceutical Services, Inc. (NYSE: WST) by 5.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 461,462 shares of the medical instruments supplier's stock after acquiring an additional 24,102 shares during
Read full article
Bank of Nova Scotia increased its holdings in shares of West Pharmaceutical Services, Inc. (NYSE: WST) by 337.8% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 65,323 shares of the medical instruments supplier's stock after buying an additional 50,402 shares
Read full article
West Pharmaceutical Services delivered a strong 2Q26, beating on both revenue ($872.3M, +13.8% YoY) and EPS ($2.37, +$0.29 vs. consensus). WST raised full-year guidance to $3.345–$3.380B in sales and $8.85–$9.05 in EPS, reflecting confidence in sustained double-digit organic growth and margin expansion. High-Value Product components and biologics drove mix shift, with HVP now 49% of revenue and biologics up 29% organically, supporting durable margin gains.
Read full article
WST tops Q2 earnings and revenue estimates, lifts its 2026 EPS outlook and sees shares surge as high-value products fuel strong growth.
Read full article
West Pharmaceutical Services, Inc. (WST) Q2 2026 Earnings Call Transcript
Read full article
While the top- and bottom-line numbers for West Pharmaceutical (WST) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read full article
West Pharmaceutical Services (WST) came out with quarterly earnings of $2.37 per share, beating the Zacks Consensus Estimate of $2.08 per share. This compares to earnings of $1.84 per share a year ago.
Read full article
West Pharmaceutical Services raised its annual profit and revenue forecasts on Thursday as strong demand for components used in injectable drugs, including diabetes and obesity treatments, helped it beat second-quarter estimates.
Read full article
Raising Full-Year Net Sales and EPS guidance EXTON, Pa., July 23, 2026 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a leading provider of innovative, high-quality injectable solutions and services, today announced its financial results for the second quarter of 2026.
Read full article
West Pharmaceutical Services NYSE: WST raised its full-year 2026 outlook after reporting second-quarter results that topped management's expectations, supported by strong demand for high-value product components, biologics-related offerings and GLP-1 elastomers.
Read full article
West Pharmaceutical Services, Inc. (NYSE:WST) reported better than expected second quarter 2026 earnings. The injectable solutions company reported adjusted earnings of $2.37 per share, beating the consensus of $2.08.
Read full article